NEW YORK, NY, Aug. 31, 2017 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative medicines and other products for targeting and treating cancer, today announced that additional clinical data from the Company’s pivotal Phase 2b trial of its novel radiotherapeutic candidate, AZEDRA® (iobenguane I 131), in patients with malignant, recurrent, or unresectable pheochromocytoma and paraganglioma (pheo/para) will be presented at the 5th International Symposium on Pheochromocytoma and Paraganglioma in Sydney, Australia. AZEDRA has not been approved for use in the United States.
“The positive outcomes from this study, which is the largest prospective clinical trial in pheo/para to date, indicate the clinical benefit and anti-tumor effects of AZEDRA,” said Dr. Daniel Pryma, Associate Professor of Radiology & Radiation Oncology and Chief, Division of Nuclear Medicine & Clinical Molecular Imaging at the Perelman School of Medicine at the University of Pennsylvania, the trial’s lead investigator. “A meaningful proportion of patients treated in this study with AZEDRA achieved a sustained reduction of antihypertensive medications which was correlated with favorable tumor responses, including radiographic tumor responses, tumor biomarker response, and overall survival. The clinical response and antitumor effects observed in this heavily pre-treated study population, along with the acceptable adverse event profile from this trial, provide a strong rationale for the potential use of AZEDRA.”
Dr. Pryma will review the data in an oral presentation entitled “AZEDRA® (iobenguane I 131) in Patients with Malignant and/or Recurrent and/or Unresectable Pheochromocytoma or Paraganglioma: Final Results of a Multi-Center, Open-Label, Pivotal Phase 2b Study.”
Trial Design and Patient Baseline Characteristics
The Phase 2b study was conducted under a Special Protocol Assessment (SPA) agreement with the Food and Drug Administration (FDA). The trial was designed to evaluate the efficacy and safety of AZEDRA in patients with malignant, recurrent, and/or unresectable pheochromocytoma or paraganglioma, which are rare neuroendocrine tumors.
A majority of patients enrolled in this study (68.9%) have had two (41.9%) or more (27.0%) prior treatments, these include surgery (89.2%), conventional MIBG I-131 (30%), and chemotherapy (37.8%). The most common locations of metastases were the lymph nodes (54.1%), bone (52.7%), lung and/or liver (50.0%).
Primary Endpoint: Reduction in Antihypertensive Medications
The study met the primary endpoint, with 17 (25%) of the 68 evaluable patients experiencing a 50% or greater reduction of all antihypertensive medication for at least 6 months. The lower limit of the 95% confidence interval was 16.15%, and the upper limit of the 95% confidence interval was 36.52%. The reduction of antihypertensive medication was sustained, with a median duration of clinical benefit of 13.3 months, ranging from 8.0 to 60.2 months. In patients who received two therapeutic doses, clinical benefit was achieved in 32%, compared to 5.6% of patients who received only one therapeutic dose.
31.4% of study patients who were not considered as responders for the primary endpoint also experienced ≥50% reduction of antihypertensive medication(s), albeit for <6 months, suggesting that there was a continuum of this clinical benefit.
Secondary Endpoints: Tumor Response Data
Treatment with AZEDRA produced favorable data for a key secondary endpoint, the proportion of study patients with overall tumor response as measured by Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Of the 64 patients with evaluable scans, confirmed partial response (PR) was achieved in 23.4% of patients (30.0% of patients receiving two doses; 0% of patients receiving one dose). Stable disease (SD) was achieved in 68.8% of all patients (68.0% of patients receiving two doses; 71.4% of patients receiving one dose). Overall, 92.2% of patients achieved tumor response of confirmed PR or SD. Persistence of antitumor effects were also evident. The proportion of study patients who experienced PR increased over time (5.9% at 3 months, to 23.5% at 12 months).
All primary endpoint responders achieved tumor response of PR/SD and 89.3% of primary endpoint non-responders also achieved tumor response of PR/SD, suggesting the potential of AZEDRA to confer multiple clinical benefits to pheo/para patients.
Tumor biomarkers were analyzed in patients that had individual tumor biomarkers above 1.5 x ULN at baseline. At 12 months following the first therapeutic dose of AZEDRA, urine and blood norepinephrine showed best response (CR/PR) rates of 42.1% and 31.0%, respectively, and urine and blood normetanephrine responder rates of 36.0% and 44.0%, respectively. In addition, serum CgA showed best response rate of 67.9%.
Median survival time as of March 10, 2017 was 36.7 months (95% CI 29.9 – 49.1) from first AZEDRA therapeutic dosing in the overall study population, and 48.73 months among patients who received two therapeutic doses, compared to 17.42 months among patients who received only one therapeutic dose. The Kaplan-Meier estimates of survival were 91.0%, 66.8%, and 51.5% at 1, 2, and 3 years, respectively, following initial therapeutic dosing. Long term follow-up continues.
The study data also suggest the potential for AZEDRA to extend survival in patients with liver or lung metastasis, which is generally considered in the literature to be less than 24 months. In this study, median survival time was similar in patients with lung or liver metastasis compared to those without (42.55 vs. 41.09 months).
Safety and Tolerability Profile
This study showed AZEDRA to be generally well tolerated. The most common treatment emergent adverse events were nausea, thrombocytopenia, anemia, fatigue, leukopenia, and neutropenia. No severe acute hypertension or hypertensive crises were observed in study patients during or immediately following AZEDRA infusion. These events are consistent with those observed in prior AZEDRA studies.
“These results are entirely consistent with the topline data announced earlier this year and further demonstrate the profound significant clinical benefit that study patients with pheo/para achieved with AZEDRA,” said Mark Baker, Chief Executive Officer of Progenics. “We are working to complete our rolling New Drug Application for AZEDRA to the FDA, and if our filing is approved, AZEDRA would be the first therapy for these rare tumors approved in the U.S.”
AZEDRA® (iobenguane I-131), a radiotherapeutic product candidate in development as a treatment for malignant and/or recurrent pheochromocytoma and paraganglioma, rare tumors found in the adrenal glands and outside of the adrenal glands, respectively. AZEDRA has been granted Breakthrough Therapy and Orphan Drug designations, as well as Fast Track status in the U.S. Under a SPA agreement with the U.S. Food and Drug Administration (FDA), a Phase 2 pivotal study has been completed in patients with malignant and/or recurrent pheochromocytoma and paraganglioma. There are currently no FDA-approved therapies for the treatment of these ultra-orphan diseases.
About Pheochromocytoma and Paraganglioma
Pheochromocytoma and paraganglioma are rare neuroendocrine tumors that arise from cells of the sympathetic nervous system. When pheochromocytomas are located outside the adrenal glands, they are called paragangliomas. Standard treatment options for these tumors include surgery, palliative therapy and symptom management. Pheochromocytoma and paraganglioma tumors frequently secret high levels of hormones that can lead to life threatening hypertension, heart failure, and stroke in these patients. Malignant and recurrent pheochromocytoma and paraganglioma may result in unresectable disease with a poor prognosis, representing a significant management challenge with very limited treatment options and no approved anti-tumor therapies.
Progenics develops innovative medicines and other technologies to target and treat cancer. Progenics' pipeline includes: 1) therapeutic agents designed to precisely target cancer (AZEDRA® and 1095), 2) PSMA-targeted imaging agents for prostate cancer (1404 and PyL™), and 3) imaging analysis tools. Progenics' first commercial product, RELISTOR® (methylnaltrexone bromide) for OIC, is partnered with Valeant Pharmaceuticals International, Inc.
This press release may contain projections and other "forward-looking statements" regarding future events. Statements contained in this communication that refer to Progenics' estimated or anticipated future results or other non-historical facts are forward-looking statements that reflect Progenics' current perspective of existing trends and information as of the date of this communication. Forward looking statements generally will be accompanied by words such as "anticipate," "believe," "plan," "could," "should," "estimate," "expect," "forecast," "outlook," "guidance," "intend," "may," "might," "will," "possible," "potential," "predict," "project," or other similar words, phrases or expressions. Such statements are predictions only, and are subject to risks and uncertainties that could cause actual events or results to differ materially. These risks and uncertainties include, among others, the cost, timing and unpredictability of results of clinical trials and other development activities and collaborations, including our clinical trials for AZEDRA and our other product candidates such as our collaboration with Valeant on the RELISTOR oral formulation and the Phase 3 clinical program for 1404; our ability to successfully integrate EXINI Diagnostics AB and to develop and commercialize its products; the unpredictability of the duration and results of regulatory review of New Drug Applications and Investigational NDAs, including our NDA for AZEDRA; market acceptance for approved products; the effectiveness of the efforts of our partners to market and sell products on which we collaborate and the royalty revenue generated thereby; generic and other competition; the possible impairment of, inability to obtain and costs of obtaining intellectual property rights; possible product safety or efficacy concerns, general business, financial, regulatory and accounting matters, litigation and other risks. More information concerning Progenics and such risks and uncertainties is available on its website, and in its press releases and reports it files with the U.S. Securities and Exchange Commission, including in its Quarterly Report on Form 10-Q for the period ending June 30, 2017. Progenics is providing the information in this press release as of its date and, except as expressly required by law, Progenics disclaims any intent or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or circumstances or otherwise.
Additional information concerning Progenics and its business may be available in press releases or other public announcements and public filings made after this release. For more information, please visit www.progenics.com. Please follow us on LinkedIn®. Information on or accessed through our website or social media sites is not included in the company's SEC filings.
CONTACT: Contact: Melissa Downs Investor Relations (646) 975-2533 firstname.lastname@example.org